Magnesium Sulphate in Perinatal Asphyxia

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Magnesium sulphate has been shown to be neuroprotective. The investigators hypothesize that magnesium sulphate infusion given to babies with perinatal asphyxia should improve outcome in the immediate neonatal period.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheri Kashmir Institute of Medical Sciences
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

• Babies eligible for the study were:

1. Term or post term

2. Less than 6 hours of age and had

3. severe perinatal asphyxia as manifested by any three of the following criteria.

• History of fetal distress (late deceleration, Loss of beat to beat variability, fetal bradycardia, meconium stained amniotic fluid)

• Need for immediate neonatal ventilation with bag and mask or through endotracheal intubation for 2 minutes or more after delivery

• A 5-minute Apgar score of < 6

• Base deficit 15 mEq/L in cord blood or admission arterial or cord blood pH 4.Moderate to severe encephalopathy

Exclusion Criteria:

• Patients with severe IUGR

• Any condition unrelated to asphyxia

• Maternal prenatal magnesium administration

• Metabolic disorder

• Chromosomal anomalies; and

• Congenital malformations were excluded from the study